Stomach Cancer – Comprehensive Medical Guide

Overview

Stomach cancer, also called gastric cancer, is a malignant disease that begins in the lining of the stomach. It most often starts as an abnormal growth (adenocarcinoma) that can spread (metastasize) to other organs if not caught early.

Globally, stomach cancer is the fifth most common cancer and the third leading cause of cancer‑related death, accounting for an estimated 1.1 million new cases and 770,000 deaths each year (World Health Organization, 2023). In the United States, the American Cancer Society reports about 27,600 new diagnoses and 11,000 deaths in 2024, representing roughly 1.5 % of all cancers.

Stomach cancer most frequently affects older adults, with a median age at diagnosis of 68 years, and is about twice as common in men as in women. Incidence varies widely by region: East Asia (particularly Japan, South Korea, and China) has the highest rates, while North America and Western Europe see comparatively lower numbers.

Symptoms

Early stomach cancer often produces vague or no symptoms, which is why many cases are diagnosed at an advanced stage. Below is a complete list of common and less‑common signs, together with brief explanations.

• Persistent indigestion or heartburn – A feeling of burning or discomfort that does not improve with antacids.
• Upper abdominal pain or discomfort – Often described as a dull ache that may worsen after meals.
• Loss of appetite – Reduced desire to eat, sometimes accompanied by an early feeling of fullness (satiety) after small amounts of food.
• Unexplained weight loss – Typically ≥5 % of body weight over a few months without dieting.
• Nausea or vomiting – May include vomiting of blood (hematemesis) if the tumor erodes a blood vessel.
• Blood in stool or black, tarry stools (melena) – Indicates bleeding in the upper gastrointestinal tract.
• Difficulty swallowing (dysphagia) – More common when the tumor is located near the gastro‑esophageal junction.
• Feeling of a lump in the abdomen – May be a palpable mass in later stages.
• Fatigue – Often secondary to anemia from chronic bleeding.
• Generalized weakness or anemia – Low hemoglobin levels detected on routine blood work.
• Persistent burping or belching – Especially after meals.
• Reflux‑type symptoms that do not respond to typical treatments – May suggest malignant involvement of the lower esophagus.

Because these symptoms overlap with many benign conditions (e.g., gastritis, peptic ulcer disease), any persistent or worsening sign should be evaluated by a healthcare professional.

Causes and Risk Factors

Stomach cancer develops when normal gastric cells acquire genetic mutations that cause uncontrolled growth. The exact cause is rarely a single factor; instead, a combination of environmental, infectious, dietary, and genetic influences contribute.

Major Risk Factors

• Helicobacter pylori infection – Chronic infection is the strongest known risk factor, responsible for up to 70 % of cases worldwide (NIH, 2022).
• Dietary patterns – High intake of smoked, salted, or pickled foods; nitrosamines; and low consumption of fresh fruits and vegetables increase risk.
• Smoking – Current smokers have a 1.5‑ to 2‑fold higher risk; risk declines after quitting.
• Heavy alcohol use – Particularly when combined with smoking.
• Family history & genetic syndromes – First‑degree relatives with gastric cancer raise risk 2‑3×. Hereditary diffuse gastric cancer (CDH1 gene mutation) and Lynch syndrome are notable inherited conditions.
• Age & sex – Incidence rises sharply after age 50; men are twice as likely as women to develop the disease.
• Previous gastric surgery – Partial gastrectomy for benign disease can increase risk.
• Obesity – Body mass index (BMI) ≥ 30 kg/m² is associated with a modest increase.
• Occupational exposure – Workers exposed to certain chemicals (e.g., rubber, coal tar, asbestos) may have elevated risk.

Pathophysiology Highlights

Most gastric cancers are adenocarcinomas, categorized as:

• Intestinal type – Linked to H. pylori, diet, and chronic gastritis; often forms gland‑like structures.
• Diffuse type – Frequently associated with CDH1 mutations; cancer cells infiltrate the stomach wall (linitis plastica), causing thickening without a discrete mass.

Diagnosis

Accurate diagnosis requires a combination of clinical evaluation, imaging, endoscopic inspection, and tissue sampling.

Initial Evaluation

• Medical history & physical exam – Focus on risk factors, symptom duration, and signs of anemia or weight loss.
• Laboratory tests – CBC (for anemia), liver function tests, tumor markers (e.g., carcinoembryonic antigen – CEA, CA 19‑9) may be ordered, though they are not definitive.

Imaging & Endoscopic Procedures

• Upper gastrointestinal (GI) endoscopy (EGD) – Gold standard; allows direct visualization, biopsy, and sometimes therapeutic interventions.
• Endoscopic ultrasound (EUS) – Stages tumor depth (T stage) and assesses regional lymph nodes.
• Contrast‑enhanced CT scan of the abdomen and pelvis – Evaluates local invasion and distant metastasis.
• Positron emission tomography (PET)‑CT – Useful for detecting metastases not seen on CT.
• Upper GI series (barium swallow) – Occasionally used when endoscopy is contraindicated.

Pathology

Biopsy specimens are examined by a pathologist to confirm malignancy, determine histologic type, grade (well‑, moderately‑, poorly‑differentiated), and test for HER2/neu overexpression, which influences treatment options.

Staging

The AJCC TNM system (Tumor, Node, Metastasis) is used to assign a stage from I (localized) to IV (advanced). Accurate staging guides therapy and prognosis.

Treatment Options

Treatment is individualized based on stage, tumor location, patient health, and preferences. Multidisciplinary care (surgery, medical oncology, radiation oncology, nutrition, and supportive services) yields the best outcomes.

Surgery

• Curative gastrectomy – Removal of part (subtotal) or whole (total) stomach with surrounding lymph nodes.
• Minimally invasive (laparoscopic/robotic) gastrectomy – Offers shorter hospital stays and faster recovery for early‑stage disease.
• palliative surgery – Bypass or stent placement to relieve obstruction when cure is not possible.

Systemic Therapies

• Chemotherapy – Common regimens include fluoropyrimidine (5‑FU or capecitabine) combined with platinum agents (cisplatin or oxaliplatin). For advanced disease, triplet regimens (e.g., FLOT: 5‑FU, leucovorin, oxaliplatin, docetaxel) improve survival.
• Targeted therapy – HER2‑positive tumors (≈20 % of cases) may receive trastuzumab (Herceptin) in combination with chemotherapy (based on the ToGA trial).
• Immunotherapy – PD‑1 inhibitors (nivolumab, pembrolizumab) are FDA‑approved for tumors with high microsatellite instability (MSI‑H) or PD‑L1 expression after prior chemotherapy.

Radiation Therapy

Used as:

• Adjuvant (post‑surgical) treatment for high‑risk stage II/III disease.
• Neoadjuvant (pre‑surgical) to shrink tumors.
• Palliative for bleeding or pain control.

Supportive & Lifestyle Measures

• Nutritional support – High‑protein, easy‑to‑digest meals; supplementation as needed.
• Pain management – WHO analgesic ladder, consider neuropathic agents.
• Psychosocial care – Counseling, support groups, and palliative‑care involvement.
• Smoking cessation & alcohol moderation – Improves treatment tolerance.

Living with Stomach Cancer

Adjusting to life after diagnosis involves practical day‑to‑day strategies.

Nutrition

• Eat small, frequent meals (5‑6 per day) to avoid early satiety.
• Choose soft, low‑fat, low‑fiber foods during recovery; gradually re‑introduce fiber as tolerated.
• Stay hydrated; sip water between bites.
• Consider oral nutritional supplements (e.g., high‑calorie shakes) if weight loss persists.
• Work with a registered dietitian experienced in oncology.

Activity & Rest

• Light walking or gentle stretching improves circulation and mood.
• Avoid heavy lifting for at least 4‑6 weeks after major surgery.
• Prioritize sleep; use sleep hygiene techniques.

Medication Management

• Take prescribed chemotherapy or targeted therapy exactly as directed.
• Report side‑effects (nausea, diarrhea, neuropathy) promptly; many can be mitigated.
• Never skip anti‑acid or ulcer‑preventing drugs if prescribed, as they protect the stomach lining.

Emotional Well‑Being

• Join support groups—online or in‑person—to share experiences.
• Seek professional counseling if you feel anxiety or depression.
• Mind‑body practices (meditation, yoga) can reduce stress.

Follow‑Up Care

Regular visits (every 3‑6 months for the first 2 years, then annually) typically include physical exam, labs, imaging, and endoscopy as indicated. Adherence to follow‑up improves early detection of recurrence.

Prevention

While not all cases are preventable, risk can be lowered through lifestyle and medical interventions.

• Eradicate H. pylori – Testing and triple therapy (antibiotic + proton‑pump inhibitor) is recommended for infected individuals, especially in high‑risk regions.
• Adopt a Mediterranean‑style diet – Emphasize fresh fruits, vegetables, whole grains, legumes, fish, and olive oil; limit smoked, salted, and processed meats.
• Quit smoking – Resources such as nicotine‑replacement therapy, counseling, or prescription meds (varenicline, bupropion) increase success.
• Limit alcohol consumption – No more than 1 drink per day for women and 2 for men.
• Maintain healthy weight – Aim for BMI 18.5‑24.9 kg/m².
• Regular medical check‑ups – For those with a strong family history, discuss screening endoscopy with a gastroenterologist.

Complications

If untreated or advanced, stomach cancer can lead to serious health problems:

• Gastric outlet obstruction – Food cannot pass, causing vomiting and severe malnutrition.
• Bleeding – Chronic or acute hemorrhage can cause anemia or life‑threatening loss.
• Peritonitis – Tumor perforation releases gastric contents into the abdominal cavity.
• Metastasis – Common sites include liver, peritoneum, lungs, and lymph nodes; leads to organ dysfunction.
• Cachexia – Complex metabolic syndrome with weight loss, muscle wasting, and decreased quality of life.
• Thromboembolic events – Cancer increases clotting risk, potentially causing deep‑vein thrombosis or pulmonary embolism.

When to Seek Emergency Care

---

Sources: Mayo Clinic, American Cancer Society, World Health Organization, National Institutes of Health, Cleveland Clinic, ToGA Trial (Lancet 2010), NCCN Guidelines for Gastric Cancer (2024).